Proteasome inhibition induces both antioxidant and hb f responses in sickle cell disease via the nrf2 pathway.

about

Cell signaling pathways involved in drug-mediated fetal hemoglobin induction: Strategies to treat sickle cell disease Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters.

P2860

Q37071189-483B8A07-1625-40E5-B21C-BB13DD1AEAC9 Q38869922-3BDDCC9C-3AD8-4E11-A3F9-449B1B2F0467

P2860

Proteasome inhibition induces both antioxidant and hb f responses in sickle cell disease via the nrf2 pathway.

Item

http://www.wikidata.org/entity/Q39011617

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Proteasome inhibition induces ...... disease via the nrf2 pathway.

@en

Proteasome inhibition induces ...... disease via the nrf2 pathway.

@nl

type

Item

label

Proteasome inhibition induces ...... disease via the nrf2 pathway.

@en

Proteasome inhibition induces ...... disease via the nrf2 pathway.

@nl

prefLabel

Proteasome inhibition induces ...... disease via the nrf2 pathway.

@en

Proteasome inhibition induces ...... disease via the nrf2 pathway.

@nl

P1476

Proteasome inhibition induces ...... disease via the nrf2 pathway.

@en

P2093

Cage S Johnson

http://www.w3.org/2001/XMLSchema#string

Stanley M Tahara

http://www.w3.org/2001/XMLSchema#string

Vijay K Kalra

http://www.w3.org/2001/XMLSchema#string

Vinod Pullarkat

http://www.w3.org/2001/XMLSchema#string

Zhuo Meng

http://www.w3.org/2001/XMLSchema#string

P2860

Oxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies.

Small molecule modulators of antioxidant response pathway.

Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model.

Sickle-cell disease.

Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases.

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.

Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions

Induction of human fetal hemoglobin via the NRF2 antioxidant response signaling pathway

Fetal hemoglobin in sickle cell anemia

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells

P304

188-195

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/03630269.2014.898651

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24670032

http://www.w3.org/2001/XMLSchema#string

P921

sickle-cell disease

Proteasome inhibition induces both antioxidant and hb f responses in sickle cell disease via the nrf2 pathway.

about

P2860

P2860

Proteasome inhibition induces both antioxidant and hb f responses in sickle cell disease via the nrf2 pathway.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921